TheraRadar
Data updated: Jun 28, 2026

TAMBOCOR (flecainide acetate) · ALVOGEN

Cardiovascular Approved 1985-10-31

TAMBOCOR is FDA-approved to treat 7 conditions (same as FLECAINIDE ACETATE).

Source: FDA Label
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
40
Years on Market

Details

Status
Discontinued
First Approved
1985-10-31
Routes
ORAL
Dosage Forms
TABLET

Companies

ALVOGEN
Active Ingredient: FLECAINIDE ACETATE

TAMBOCOR Approval History

1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
16 FDA actions from 1985 to 2016
Sep 2016 SUPPL
Mfg · Manufacturing (CMC)
FDA Letter Label
Apr 2000 SUPPL
Mfg · Manufacturing (CMC)
Sep 1999 SUPPL
Mfg · Manufacturing (CMC)

What TAMBOCOR Treats

7 indications

TAMBOCOR is approved for 7 conditions since its original approval in 1985. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Supraventricular Tachycardia
  • Atrioventricular Nodal Reentrant Tachycardia
  • Atrioventricular Reentrant Tachycardia
  • Atrial Fibrillation
  • Atrial Flutter
  • Ventricular Arrhythmia
  • Ventricular Tachycardia

Same approved indications as FLECAINIDE ACETATE (same active ingredient).

Source: FDA Label
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT03539302 INSTANT results posted FLE-002 Ph 2 completed INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TAMBOCOR FDA Label Details

Indications & Usage

FDA Label (PDF)

TAMBOCOR is FDA-approved to treat 7 conditions — same approved indications as FLECAINIDE ACETATE.

Track TAMBOCOR with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA018830 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.